Literature DB >> 19787846

Cost of home palliative care compared with conventional hospital care for patients with haematological cancers in Greece.

Sofia Tzala1, Joanne Lord, Nikolaos Ziras, Panayotis Repousis, Anna Potamianou, Evangelia Tzala.   

Abstract

This study compared the costs of home palliative with conventional hospital care for cancer haematological patients in Greece. The study was a retrospective cost-minimisation analysis using data from the finance department and from patient notes for the period from January to June 2002. A non-parametric bootstrap method was used to estimate the incremental cost between home and conventional care. A sensitivity analysis was also used. The estimated incremental cost was euro 522 (95% confidence interval: euro 516-528). This was not substantially affected by varying the unit costs within reasonable limits and remained statistically significant under all scenarios tested in the sensitivity analysis. Our findings show that home palliative care is more expensive than conventional hospital care. Further studies should be carried out to examine the cost-effectiveness of the particular scheme as well as the preferences of patients and carers.

Entities:  

Mesh:

Year:  2005        PMID: 19787846     DOI: 10.1007/s10198-004-0266-x

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  2 in total

1.  Hospice at home service: the carer's perspective.

Authors:  Dorry McLaughlin; Kate Sullivan; Felicity Hasson
Journal:  Support Care Cancer       Date:  2006-08-30       Impact factor: 3.603

2.  Evaluation design of the patient-centred pathways of early palliative care, supportive ecosystems and appraisal standard (InAdvance): a randomised controlled trial.

Authors:  Junwen Yang-Huang; Ascensión Doñate-Martínez; Jorge Garcés; Maria Soledad Gimenez Campos; Raquel Valcarcel Romero; Maria-Eugenia Gas López; Adriano Fernandes; Mariana Camacho; Ana Gama; Sofia Reppou; Panagiotis D Bamidis; Gordon Linklater; Frances Hines; Jude Eze; Hein Raat
Journal:  BMC Geriatr       Date:  2022-10-21       Impact factor: 4.070

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.